-
Biopharma Leaders Unite To Stand With Science
drugs.com
September 24, 2020
The CEOs today announced a historic pledge, outlining a united commitment to uphold the integrity of the scientific process as they work towards potential global regulatory filings and approvals of the first COVID-19 vaccines.
-
Biopharma increasingly factoring sustainability into cold chain decisions
europeanpharmaceuticalreview
July 31, 2020
A survey has found that the biopharma industry is taking sustainability into their cold chain considerations more and more, with 66 percent saying it is very important.
-
WuXi Biologics to Open Clinical Mfg. Facility in Cranbury, NJ
contractpharma
June 10, 2020
Will install total 6000 L bioreactors, Process Development (PD), Quality Control (QC) labs, along with supporting functions.
-
Financial Report -Pfizer
contractpharma
April 30, 2020
Biopharma revenues up 11% in the quarter to $10.0 billion; generic competition impacts Upjohn revenues.
-
Cambrex Completes Biopharma Expansion
contractpharma
April 08, 2020
The Durham, NC site now features a range of new instruments, including particle analysis and imaging.
-
Biopharma industry leaders collaborate to combat COVID-19
europeanpharmaceuticalreview
March 30, 2020
The International Federation of Pharmaceutical Manufacturers and Associations has announced that the biopharma industry has responding swiftly to the COVID-19 pandemic and will further increase its efforts.
-
Thermo Fisher Scientific Continues Biopharma Investments
contractpharma
March 24, 2020
Further invests $475 million in biopharma capabilities to help accelerate commercialization.
-
The top 10 largest biopharma M&A deals in 2019
fiercepharma
January 07, 2020
Biopharma M&A got a big boost moneywise in 2019. The three largest—Bristol-Myers Squibb for Celgene, AbbVie for Allergan, and Amgen for Celgene’s psoriasis drug Otezla—together delivered more than $150 billion. Valued?at $74 billion ...
-
Evolving World of Pharma: Demand for biologics is predicted to grow at 10% per year over the next 4-5 years
Sarah Harding
November 24, 2019
As biopharmaceuticals continue to grow at a rapid place, a number of trends are impacting industry.
-
U.S. biopharma CEOs look outside for growth, poll finds
fiercepharma
September 26, 2019
Eli Lilly went after Loxo Oncology to beef up its presence in cancer treatment, just as Amgen is?paying?$13.4 billion for Celgene’s Otezla to secure a larger share of the psoriasis market alongside old TNF drug Enbrel.